IceCure Medical Reports 70% Increase in U.S. ProSense Install Base
IceCure Medical reported a 70% increase in its U.S. active commercial install base of ProSense for breast cancer cryoablation following FDA marketing authorization in October 2025, reflecting accelerating commercial adoption, expanding physician demand and continued growth in the Company's U.S. footprint. IceCure develops and commercializes its minimally invasive cryoablation technology that destroys tumors by freezing, offering an option to surgical tumor removal for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgery.
